Physician profile
Angela Mclaughlin
NPI 1730599762
$1,785.37
in general payments reported to CMS, 2019-2025
26 companies · $317 in 2025
The $317 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.29 · 2020: $121 · 2021: $291 · 2022: $319 · 2023: $223 · 2024: $425 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $964.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $340.77 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $304.81 | 2021-2024 | |
| Amgen INC. | $232.68 | 2019-2025 | Evenity, Prolia, Tavneos |
| Astellas Pharma US INC | $132.84 | 2023-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $105.49 | 2020-2024 | |
| Lilly USA, LLC | $93.54 | 2021-2024 | Mounjaro |
| Pfizer INC. | $79.20 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $70.67 | 2022-2025 | |
| Collegium Pharmaceutical, INC. | $47.23 | 2024 | Xtampza |
| E.R. Squibb & Sons, L.L.C. | $41.79 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.21 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $34.84 | 2022-2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $32.99 | 2021-2023 | Fasenra |
| Merck Sharp & Dohme LLC | $29.93 | 2022 | |
| Daiichi Sankyo INC. | $24.71 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $24.54 | 2021 | |
| Dexcom, INC. | $17.70 | 2025 | Dexcom G6 Transmitter |
| Biogen, INC. | $16.76 | 2022 | |
| Alexion Pharmaceuticals, INC. | $16.63 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $16.06 | 2025 | Austedo Xr |
| Rhythm Pharmaceuticals, INC. | $15.84 | 2023 | Imcivree |
| Biohaven Pharmaceutical Holding Company LTD. | $14.51 | 2022 | |
| Philips North America LLC | $13.58 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $12.84 | 2022 | |
| Glaxosmithkline, LLC. | $12.27 | 2021 | |
| Aerin Medical INC. | $11.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.